• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Tactile Systems Technology Inc.

    5/30/25 4:48:49 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care
    Get the next $TCMD alert in real time by email
    SD 1 tm2516665d1_sd.htm FORM SD

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM SD
    Specialized Disclosure Report

     

      Tactile Systems Technology, Inc.  
      (Exact Name of Registrant as Specified in its Charter)  

     

    Delaware   001-37799 41-1801204
    (State or other jurisdiction of
    incorporation)
      (Commission File Number)

    (I.R.S. Employer

    Identification No.)

     

    3701 Wayzata Blvd, Suite 300
    Minneapolis, Minnesota
      55416
    (Address of principal executive offices)   (Zip Code)
         

      Elaine M. Birkemeyer
    (612) 355-5100
     
      (Name and telephone number, including area code,
    of the person to contact in connection with this report.)
     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ¨Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____________.

     

     

     

     

     

     

    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases.

     

    This Form SD of the Company is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Rule”), for the reporting period from January 1, 2024 to December 31, 2024. The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which Conflict Minerals are necessary to the functionality or production of those products. For the purposes of the Rule, “Conflict Minerals” is defined as columbite-tantalite (coltan), cassiterite, gold, wolframite, or their derivatives, which are limited to tantalum, tin, and tungsten (“3TG”), or any other material or derivatives determined by the Secretary of State to be financing conflict in the Covered Countries. “Covered Countries” are the Democratic Republic of the Congo (the “DRC”) and Adjoining Countries. The Rule defines Adjoining Countries as countries that share an internationally recognized border with the DRC (the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia, and Angola).

     

    The products that we manufactured or contracted to have manufactured during the reporting period include the following:

     

    ·Our proprietary Flexitouch system, which is an advanced intermittent pneumatic compression device used for at-home treatment for lymphedema patients;

     

    ·Our proprietary Entre system, which is a basic pneumatic compression device used for at-home treatment for patients with chronic swelling;

     

    ·Our proprietary Nimbl system, which is our next generation pneumatic compression device used for at-home treatment for patients with upper extremity lymphedema; and

     

    ·Our proprietary AffloVest respiratory therapy system, which is a portable, battery-powered wearable vest, that treats patients with chronic respiratory conditions such as chronic obstructive pulmonary disease-associated breathing conditions like bronchiectasis, or conditions resulting from neuromuscular disorders and cystic fibrosis, by managing airway clearance.

     

    With respect to these products that we either manufactured or contracted to have manufactured in calendar year 2024, we have determined the presence of tantalum, tin, gold and tungsten in printed circuit board assemblies, wire harness assemblies and certain valve assemblies contained in our Flexitouch, Entre, Nimbl and Afflovest systems (the “Covered Products”). Therefore, we have conducted a reasonable country of origin inquiry (“RCOI”) as required by the Rule to determine whether any components provided to us by our suppliers to manufacture the Covered Products or components used by our contract manufacturers to manufacture the Covered Products originated in a Covered Country or are from recycled or scrap sources.

     

    Reasonable Country of Origin Inquiry

     

    We conducted our RCOI by identifying those direct suppliers that provided components that may contain 3TG for the Covered Products that we manufactured or contracted to manufacture during the calendar year ended December 31, 2024. We obtained information from these suppliers, as well as our contract manufacturers (the “Respondents”), by requesting a completed copy of a Conflict Minerals Reporting Template (“CMRT”) developed by the Responsible Minerals Initiative (“RMI”) related to those components supplied to us or any products manufactured for us by our contract manufacturers to determine the country of origin of any 3TG used in the Covered Products. We reviewed and analyzed the CMRTs that we received from the Respondents with regard to the components used in the Covered Products. We received a completed copy of the CMRT from all but one of our suppliers and contract manufacturers or 90% of those suppliers and contract manufacturers that we contacted. The one Respondent who did not return to us a completed CMRT has historically filed a Form SD and a conflict minerals report, but its report for the reporting year ending December 31, 2024 is not yet on file. Last year, the Respondent disclosed in its conflict minerals report that it determined that some of the smelters identified by its suppliers are located in Covered Countries and some of the smelters are not on the list certified by the RMI as conformant with the Responsible Minerals Assurance Process (“RMAP”) assessment protocols.

     

     

     

     

    Two of the Respondents that completed a CMRT reported that the Respondents do not intentionally add or use 3TG in their production process. Five of the Respondents that completed a CMRT reported information on a “product level,” but two of these responses were of limited utility to us because neither of these Respondents identified any of the smelters and refiners supplying 3TG to their supply chains so we could not cross-check the smelters and refiners against RMI’s publicly available database of smelters and refiners that are conformant with the RMAP assessment protocols. With respect to two of the other three responses we received that reported on a “product level,” we were unable to confirm that all of the tantalum, tin, and tungsten smelters and gold refiners listed in the CMRT are currently listed as certified by RMI as conformant with the RMAP assessment protocols. With respect to the final response that we received from a Respondent that reported on a “product level,” we were able to confirm that as of May 21, 2025, all of the tin smelters listed in the CMRT were listed as certified by RMI as conformant with RMAP assessment protocols.

     

    Two of the Respondents that completed a CMRT reported information on a “company level” that included 3TG information for all products sold by that supplier during the reporting year, even though we purchased only a limited subset of such products from these suppliers. With respect to one of these, we were unable to confirm, as of May 21, 2025, that all of the tantalum, tin, and tungsten smelters and gold refiners listed in the CMRT are currently listed as certified by RMI as conformant with the RMAP assessment protocols. With respect to the other, we were able to confirm that as of May 21, 2025, all of the tin smelters listed in the CMRT provided by that Respondent were currently listed as certified by RMI as conformant with the RMAP assessment protocols, although we could not confirm that all of the tantalum and tungsten smelters and gold refiners were conformant with RMAP assessment protocols.

     

    Conflict Minerals Disclosure

     

    In light of the information we received from our suppliers as part of our RCOI, we are unable to definitively determine whether all the tantalum, tin, tungsten and gold used in the Covered Products may have originated in Covered Countries or are from recycled or scrap sources. We will continue to engage with our suppliers to obtain current, accurate and complete information related to their supply chain.

     

    This Form SD is publicly posted on our webpage at http://investors.tactilemedical.com/corporate-governance under “Conflict Minerals Disclosure.” The content of any referenced website is not incorporated by reference into and should not be considered part of this Form SD.

     

    Pursuant to the Public Statement issued by the SEC’s Division of Corporate Finance on April 7, 2017, we have provided only the disclosure required under the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD, and the Company has chosen not to file, as an exhibit to this Form SD, the Conflict Minerals Report otherwise required by Item 1.01(c).

     

    Item 1.02 Exhibit

     

    None.

     

     

     

     

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01 Resource Extraction Issuer Disclosure and Report

     

    Not applicable.

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

    None.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    TACTILE SYSTEMS TECHNOLOGY, INC.

     

    By: /s/ Elaine M. Birkemeyer Date: May 30, 2025
      Elaine M. Birkemeyer  
      Chief Financial Officer  

     

     

     

    Get the next $TCMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCMD

    DatePrice TargetRatingAnalyst
    5/6/2025$14.00Overweight → Neutral
    Piper Sandler
    2/19/2025$23.00 → $18.00Buy → Neutral
    B. Riley Securities
    11/5/2024Outperform → Perform
    Oppenheimer
    11/5/2024Buy → Neutral
    BTIG Research
    9/26/2024$23.00Buy
    B. Riley Securities
    More analyst ratings

    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tactile Medical to Present at Upcoming Investor Conferences in June

      MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will be participating in two upcoming investor conferences. Tactile Medical is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 3:20 p.m. CST and at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 2:35 p.m. EST. Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 3:20 p.m. CST Event: Jefferies Global Healt

      5/20/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

      MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

      5/5/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the

      4/21/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tactile Systems downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Tactile Systems from Overweight to Neutral and set a new price target of $14.00

      5/6/25 8:04:03 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Tactile Systems from Buy to Neutral and set a new price target of $18.00 from $23.00 previously

      2/19/25 7:05:55 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems downgraded by Oppenheimer

      Oppenheimer downgraded Tactile Systems from Outperform to Perform

      11/5/24 7:15:44 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Financials

    Live finance-specific insights

    See more

    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TCMD
    SEC Filings

    See more
    • Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

      MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

      5/5/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the

      4/21/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versus $8.2 million in Q4 2023Adjusted EBITDA of $16.2 million versus $15.4 million in Q4 2023Expanded launch of Nimbl to include patients with lower extremity lymphedemaAppointed Laura King to Board of

      2/18/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Birkemeyer Elaine M. sold $29,037 worth of shares (2,921 units at $9.94), decreasing direct ownership by 3% to 99,111 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/14/25 5:26:59 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Dodd Sheri Louise sold $30,955 worth of shares (3,149 units at $9.83), decreasing direct ownership by 2% to 181,241 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/12/25 4:34:53 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Director Burke William W was granted 16,078 shares and sold $31,911 worth of shares (3,300 units at $9.67), increasing direct ownership by 36% to 48,520 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/9/25 4:28:47 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Tactile Systems Technology Inc.

      SD - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/30/25 4:48:49 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/9/25 4:56:54 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Tactile Systems Technology Inc.

      S-8 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/7/25 3:41:56 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

      SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 7:29:11 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 5:04:27 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/8/24 3:21:42 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Tactile Medical Appoints Laura King to Board of Directors

      MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE

      1/13/25 8:00:00 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • LifeLens Technologies Expands Executive Leadership Team and Board of Directors

      PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea

      11/8/23 7:30:00 AM ET
      $INSP
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical Appoints Vindell Washington, M.D. to Board of Directors

      MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s

      10/2/23 4:05:00 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care